- A presidential order established executive authority, mandating the Department of Health and Human Services to execute orders and prompting the CDC to review scientific assessments with ACIP.
- HHS received federal funding and issued directives limiting care under the Trump administration.
- Trump pressured ministers to accept a drug spending deal.
- The NHS and NICE conducted analysis and decided on drug benefits and costs, linked to a trade deal intended to appease the Trump administration.
NICE to Appraise Testosterone Cream for Cost Effectiveness in England
What happened
The National Institute for Health and Care Excellence must appraise a female-formulated testosterone cream, AndroFeme, for cost effectiveness in England. Although the UK approved the cream in 2025, it is not yet available through the National Health Service because NICE has not completed its cost-effectiveness review. In England, NHS prescriptions for testosterone gel for women increased roughly tenfold between 2015 and 2022.
From theweek.com
Why it matters
The appraisal determines whether the National Health Service will fund the cream, directly influencing drug spending and healthcare resource allocation in England. This evaluation is part of a larger context where the NHS and NICE conduct analyses on drug benefits and costs linked to a trade deal intended to appease the Trump administration.
The National Health Service and the National Institute for Health and Care Excellence conduct analysis on drug benefits and costs, which is linked to a trade deal intended to appease the Trump administration.
From theweek.com
Who's involved
- National Institute for Health and Care ExcellenceResponsible for evaluating the cost-effectiveness of the cream and setting healthcare standards in England.
- National Health ServiceThe publicly-funded healthcare system that must follow NICE recommendations regarding drug funding.
- EnglandThe geopolitical state where NICE provides guidelines and resource allocation standards.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- National Health ServiceSpeculative
The National Health Service might face changes in drug procurement and funding based on NICE's cost-effectiveness recommendation.
Keep exploring
The entities involved
-
England
country in north-west Europe, part of the United Kingdom
-
National Institute for Health and Care Excellence
non-departmental public body of the Department of Health in the United Kingdom
Nothing else this week.